FGFR2 and infantile convulsions and choreoathetosis: FGFRi treatment in previously treated patients with advanced iCCA containing FGFR2 fusions/rearrangements resulted in response rates of 21–40%, disease control rates of ~80%, and mPFS of 7–9 months [29,30,31,32].